Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The …
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism …
TransCon PTH (palopegteriparatide, approved under the brand name YORVIPATH in the European Union and certain other countries as a replacement therapy indicated for the …
Yorvipath for Hypoparathyroidism - HealthCentral
Jan 29, 2025 · What Does Research Show About Yorvipath for Hypoparathyroidism? The FDA approved Yorvipath based on evidence from a clinical trial involving 82 adults with chronic …
YORVIPATH: First Hypoparathyroidism Treatment in Adults
Aug 16, 2024 · YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range …
Your Guide to Yorvipath for Hypoparathyroidism - WebMD
Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D treatment.
FDA approves new drug for hypoparathyroidism, a rare disorder
The FDA has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism. Yorvipath was not studied in adults with acute post-surgical …
Yorvipath - European Medicines Agency (EMA)
Sep 15, 2023 · Overview Yorvipath is a hormone replacement medicine for treating adults with chronic hypoparathyroidism. In patients with this condition, the parathyroid glands in the neck …
Yorvipath Approved for Treatment of Hypoparathyroidism
Aug 16, 2024 · The Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in …
FDA approves hypoparathyroidism treatment Yorvipath
Aug 14, 2024 · Hypoparathyroidism is considered chronic if it persists for longer than six months. Yorvipath contains palopegteriparatide, a prodrug that is modified in the body over time into …
Yorvipath: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 13, 2024 · Yorvipath (palopegteriparatide) is a long-acting parathyroid hormone analog that releases PTH (1-34) throughout the day, which temporarily restores physiologic levels of …